Best Healthcare Companies in Israel
The 269 best Healthcare companies in Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Taro.
Israel's Healthcare sector is more active than the funding headlines suggest. We're tracking 269 companies here, with $602M in total disclosed funding, and the spread tells a story: ThermoMind leads the directory at $16M raised, XTL Biopharmaceuticals follows at $11M, and the median sits far lower, which means most of this ecosystem is still early and hungry. No unicorns yet. But the underlying market these companies are building into is enormous, with global healthcare projected to cross $2 trillion and climb toward $2.6T by 2025 at a 6.3% CAGR, driven by consumers demanding more convenient, virtual-first care delivery. Strict compliance to product safety adds friction, sure, but it also filters for founders who've done the hard regulatory work.
So what's actually moving right now? Vaccine-related themes, including candidates, trials, and immunogenicity research, are dominating sector attention even as overall coverage stays flat. App adoption is a real signal too: median install growth across healthcare apps is running at roughly +16% YoY across 53 tracked apps, which isn't noise. And as implementing AI inside health organizations becomes a boardroom priority globally, Israeli startups with deep biodesign and therapeutics DNA, think Scala Biodesign and Entera Bio, are well-positioned to catch that wave. If you're mapping this space, the directory below is your starting point.
- Global Healthcare to Soar Above $2 Trillion in 2020 with Consumerism a
- Healthcare Consumers in Asia-Pacific Prefer a Single Touchpoint
Ranked: Best Healthcare companies in Israel
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Taro Manufacturer of topical prescription products including creams ointments and gels | $60M | 276 mo ago | 129 | 1950 | — | 3 signals ▼25% Lawsuit | — | — |
| 2 | Kanfit3D Manufacturer of custom implants solutions and surgeon specific instruments | $53M | 77 mo ago | 6 | 2016 | Samuel Rosenbaum Co-Founder & CEO | — | — | — |
| 3 | FutuRx Startup accelerator and incubator focused on Biotech | $50M | 84 mo ago | 18 | 2013 | Kinneret Livnat-Savitzky CEO | — | — | — |
| 4 | Pharma Two B Pharma Two B is a late-stage pharmaceutical company developing innovative combination products of previously… | $38M | 111 mo ago | 12 | 2007 | — | — | 75 patents Patents concentrated in health & consumer products | — |
| 5 | Medi-Tate Standalone general clinic | $37M | 91 mo ago | 8 | 2007 | — | — | 62 patents Urological implants for drug delivery and structural support in bladder and prostate treatments. | — |
| 6 | SpliSense Limited information available | $29M | 61 mo ago | 13 | 2016 | — | — | 51 patents Patents concentrated in chemistry & materials | — |
| 7 | AmplioSpeech Provider of digital speech-language therapy services | $27M | 62 mo ago | 157 | 2014 | — | — | — | — |
| 8 | Can-Fite Developer of small molecules for autoimmune-inflammatory and cancer diseases | $26M | 53 mo ago | 8 | 1994 | Pnina Fishman Co-Founder & CEO | — | 264 patents A3 adenosine receptor agonist therapeutics for inflammatory and oncologic diseases | — |
| 9 | Procognia Contract research services for glycosylation and protein function studies | $24M | 259 mo ago | — | 2000 | Nir Peleg Ceo | — | 14 patents Glycan and carbohydrate polymer analysis for diagnostic and biomarker applications | — |
| 10 | BioLineRx Clinical stage biopharmaceutical development company | $23M | 138 mo ago | 49 | 2003 | Avi Molcho Co-Founder | — | 234 patents CXCR4 antagonist drugs for stem‑cell mobilization and oncology therapies | 1 launch |
| 11 | Mileutis Developing peptide-based antibiotics for human and animal health | $20M | 67 mo ago | 38 | 2005 | David Javier Iscovich CEO | — | 84 patents Improving dairy milk composition and casein‑derived therapeutic formulations for skin and mammary health | — |
| 12 | Kadimastem Stem Cell for the treatment of diabetes mellitus and amyotrophic lateral sclerosis (ALS) | $18M | 55 mo ago | 31 | 2009 | — | 3 signals ▼50% M&A | 54 patents Generation and purification of pancreatic endocrine cells for therapeutic applications | 1 partnership |
| 13 | Cytora Developer of stem cell technology for chronic wounds and autoimmune disorders | $17M | 60 mo ago | 8 | 2018 | — | — | 6 patents Stem cell cryopreservation formulations and neuroregenerative cell therapy methods. | 3 partnerships |
| 14 | Proteologics Ubiquitin system-based drugs for cancer & infectious diseases | $17M | 295 mo ago | — | 1999 | — | — | 49 patents Small-molecule inhibitors of POSH/AP and ubiquitin ligases for inflammatory disease therapy | — |
| 15 | ThermoMind Provider of non-invasive breast cancer screening technology using AI and multimodal sensing | $16M | 39 mo ago | 10 | 2022 | Larisa Adamyan Co-Founder and Chief Security Officer (Chief Scientific Officer) | — | — | — |
| 16 | Salignostics Saliva-based RDT for pregnancy detection, ovulation prediction & malaria diagnosis | $16M | 50 mo ago | 13 | 2015 | — | — | 22 patents Saliva-based point‑of‑care electrochemical detection and sample verification diagnostics. | — |
| 17 | Quantomix Provider of electron & ion detection services for research, medical, and industrial applications | $12M | 262 mo ago | 17 | 2000 | Zachi Berger Co-Founder | — | 9 patents SEM sample enclosures for fluid analysis and metabolic diagnostic device technologies | — |
| 18 | Pangea Biomed Proprietary platform offering response prediction for dozens of cancer types | $12M | 42 mo ago | 21 | 2018 | Eyal Gottlieb Founder | — | 9 patents AI-based histopathology image analysis and gene interaction mapping for cancer therapy response prediction. | — |
| 19 | XTL Biopharmaceuticals Protein therapeutics for inflammatory diseases such as systemic lupus erythematosus and multiple myeloma. | $11M | 22 mo ago | 4 | 1993 | — | 12 signals ▲50% Announcements · Leadership · M&A | 24 patents Peptide lupus therapeutics and heterocyclic small‑molecule antivirals for HCV | — |
| 20 | Picodya Manufacturer of POC IVD | $10M | 70 mo ago | 29 | 2017 | Eli Simon Co-Founder & Chairman | — | — | — |
| 21 | Dynamix Pharmaceuticals Developing small molecule kinase II inhibitors for cancer and autoimmune diseases | $10M | 208 mo ago | 11 | 2009 | Oren Becker Founder | — | 9 patents Patents concentrated in chemistry & materials | — |
| 22 | Entera Bio Developing parathyroid hormone for hypoparathyroidism, osteoporosis and bone healing | $10M | 29 mo ago | 21 | 2010 | — | — | 133 patents Oral delivery of peptide therapeutics via acid‑neutralizing polymer formulations | — |
| 23 | FeelBetter Provider of clinical intelligence services for healthcare organisations | $8M | 34 mo ago | 15 | 2018 | Liat Primor Co-Founder & CEO | — | 6 patents AI-driven clinical risk stratification and automated medication management systems | — |
| 24 | ELGAN Pharma Manufacturer of neonatology-focused gestational therapies | $8M | 35 mo ago | 16 | 2018 | Stav Zeldis Co-Founder and VP Regulatory Affairs | — | 56 patents Neonatal drug formulations for insulin, oxytocin, and retinopathy treatments | — |
| 25 | Alpha Omega Developer of neurosurgical and neuroscience equipment and software | $7M | 83 mo ago | 23 | 1993 | — | 5 signals ▼44% Leadership · New product · M&A | 65 patents Neurostimulation lead placement and navigation systems for brain surgery | 2 partnerships |
| 26 | OurRitual Provider of relationship support through expert sessions and digital exercises | $7M | 22 mo ago | — | 2021 | Gilad Meir Co-Founder | — | — | — |
| 27 | Sequentify Provider of library-prep solutions for next-generation sequencing | $7M | 49 mo ago | 16 | 2021 | — | — | 3 patents Targeted DNA sequencing using embedded molecular inversion probe technologies | — |
| 28 | Scala Biodesign Provider of computational protein design solutions at scale | $6M | 2 mo ago | — | 2021 | Adi Goldenzweig Co-Founder & CTO | — | — | 1 partnership |
| 29 | SilverStream Manufacturer of wound healing products | $4M | 197 mo ago | 106 | 2001 | Alon Raivit Co-Owner | — | — | 1 award |
| 30 | GemmaCert Provider of an analytical device for the verification of the potency of cannabis flowers | $3M | 100 mo ago | 22 | 2015 | Dana Yarden Co-Founder | — | 14 patents Analytical testing of plant material potency and quality using spectroscopic methods | — |
| 31 | Scinai Provider of immuno-therapeutics solutions for the healthcare industry | $3M | 29 mo ago | 33 | 2023 | — | 5 signals ▼62% Funding · Regulatory · Earnings | — | — |
| 32 | MICA Provider of AI based decision support system services for radiologists | $3M | 40 mo ago | 11 | 2018 | — | — | — | — |
| 33 | Evinature Provider of women health online assessment services | $2M | 42 mo ago | 12 | 2011 | Nir Salomon Co-Founder and Head of R&D | — | 6 patents Herbal combination formulations for treating inflammatory bowel and diverticular diseases | — |
| 34 | PixCell Cell-based diagnostics for POC usage | $2M | 68 mo ago | 76 | 2009 | — | — | — | — |
| 35 | BioMAS Tellurium-based integrin inhibitors for range of indications | $2M | 147 mo ago | 34 | 2000 | Benjamin Sredni Co-Founder | — | 110 patents Patents concentrated in health & consumer products | — |
| 36 | Optimata Develops technologies for predicting improved patient therapy and manufactures medical devices for oncology | $2M | 101 mo ago | 11 | 2000 | Zvia Agur Founder & CSO | — | 39 patents AI-driven predictive analytics for personalized medical treatment outcomes | — |
| 37 | Forrest Innovations Developer of proprietary technology platform against mosquito-borne diseases | $1M | 126 mo ago | 12 | 2013 | Nitzan Paldi Ceo | — | 33 patents Biotech pest management: insect pupae sorting, mosquito control, and plant pathogen mitigation | — |
| 38 | Engineering for All Provider of point of care diagnostic device | $900K | 26 mo ago | 12 | 2016 | Yoel Ezra Founder & CEO | — | — | — |
| 39 | GeneGrafts Cell-therapy for neurological disorders and cardiac arrhythmias. | $800K | 270 mo ago | 1 | 2003 | Yair Feld Founder & CEO | — | 26 patents Gene therapy targeting KV1.3 ion channels to modulate electrophysiology of excitable tissues | — |
| 40 | Cell Source Cell therapy treatments for transplantation, cancer treatment and reversal of vital organ disease 7Funding top 48%Global bottom 38%Market bottom 20% All 3 signals ▾Fundingtop 48% Globalbottom 38% Marketbottom 20% Funding: Raised $398k across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Global: Serving 2 countries incl. United States, Israel rank vs industry peers · Fliar Intelligence Index 7/100 | $398K | 5 mo ago | 1 | 2011 | — | — | — | — |
| 41 | Medibrane Manufacturer of medical device components using advanced polymer coating technologies | $383K | 84 mo ago | 20 | 2014 | Amir Kraitzer Founder and CTO | — | 18 patents Manufacturing bonded stent assemblies and 3D‑printed catheter shafts for minimally invasive devices | 2 launchs |
| 42 | 22seeds Manufacturer of alternative medicines | $250K | 152 mo ago | — | 2010 | Dori Dayan Co-Founder & CMO | — | — | — |
| 43 | Israel Cannabis Retailer of computer hardware, peripherals, and accessories | $200K | 78 mo ago | 18 | 2015 | — | — | — | — |
| 44 | Earways Medical Manufacturer of ear care products | $111K | 81 mo ago | 4 | 2014 | Amir Kraitzer Founder and CTO | — | — | — |
| 45 | EIO Biomedical Medical device for prevention of post-surgical adhesions | $58K | 94 mo ago | 3 | 2016 | Yair Pilpel Founder & CEO | — | 9 patents Anti-adhesion biomaterials for surgery and closed-system plasma protein purification technologies. | — |
| 46 | ultrasound simulator Provider of ultrasound training services | $55K | 82 mo ago | — | 2018 | Eliad Moshe Co-Founder | — | — | — |
| 47 | Pluri Developer of three-dimensional cell expansion platforms for various industries | — | 2 mo ago | 134 | 2003 | Yaky Yanay CEO | — | — | — |
Top 12 Healthcare companies in Israel
#1
Series A · Tel Aviv, Tel Aviv · founded 2021$5.5Mraised▾
It is a company that specializes in computational protein design solutions. They offer unique one-shot solutions to increase value and accelerate protein design processes.
- Mar 2026Series A$16M
- Sep 2023Seed$5.5M
#2
Public · Tel Aviv, Tel Aviv · founded 2011 · 1 employees$397.5Kraised▾
Cell Source is a biotechnology company developing cell therapy treatments based on the management of immune tolerance. Its flagship technology is the Veto Cell platform. Veto cells are white blood cells taken from either the patient or a healthy third-party donor. They are then processed using a mix of off-the-shelf cytokines that change their characteristics and activate their inherent “attacker blocking” capability. The company also has Megadose, a treatment involving a large number of stem cells to facilitate bone marrow transplants in cases with partially-matched donors. It is working on Megadose-drug combination platforms. It currently has 2 Megadose + drug combinations (PoC and pre-clinical stages) and 2 pre-clinical Veto cell programs for anti-rejection and anti-lymphoma.
- Jan 2026Post IPO$1.5M
- Oct 2023Post IPO$3.9M
- Oct 2019Post IPO$8.9M
- Nov 2015Seed$252.5K
#3
Public · Ra anana, Center District · founded 1993 · 4 employees$10.6Mraised▾
XTL Biopharmaceuticals focuses on the acquisition and development of late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company has two product candidates in clinical development: hCDR1 peptide for the treatment of Systemic Lupus Erythematosus (SLE) (Phase 2); Recombinant Erythropoietin (rHuEPO) for the prolongation of multiple myeloma (MM) advanced-stage patients’ survival (Phase 1).
#4
Seed · Tel Aviv, Tel Aviv · founded 2021$7.2Mraised▾
Provider of relationship support through expert sessions and digital exercises. The company offers weekly sessions with licensed professionals, available around the clock. It pairs these sessions with science-backed digital exercises tailored to individual needs. The company provides ongoing support to help individuals achieve their relationship goals.
- Jul 2024Seed$5.2M
- Oct 2022Seed$2M
#5
Public · Jerusalem, Jerusalem District · founded 2010 · 21 employees$9.5Mraised▾
Entera Bio is a clinical stage company focussed on the development of drugs based on its drug delivery platform which can be used for the oral delivery of large molecule protein APIs. It claims that its technology combines drug delivery entities to increase its half-life and bioavailability and thereby protects the large molecules and peptides in the GI tract. Its lead candidate PTH- 1-34 (Teriparatide) is an oral formulation of the active element of the parathyroid hormone which is being developed for hypoparathyroidism, osteoporosis and bone healing.
- Dec 2023Post IPO$6.6M
- Dec 2019Post IPO$14.3M
- Oct 2017Series A$2M
- Jul 2016Series A$7.5M
#6
Funding Raised · Haifa, Haifa District · founded 2022 · 10 employees$16.2Mraised▾
Provider of non-invasive breast cancer screening technology using AI and multimodal sensing. It combines Dynamic Multimodal Imaging, artificial intelligence, immediately detect and track biomarkers related metabolic abnormalities caused by cancer cells.
- Feb 2023Grant (prize money)$12.3M
- Jan 2023Grant (prize money)$3.9M
#7
Funding Raised · Nazareth, Northern District · founded 2018 · 16 employees$7.5Mraised▾
Manufacturer of neonatology-focused gestational therapies
- Jul 2023Grant (prize money)$2.5M
- Nov 2022Grant (prize money)$2.3M
- 2022Grant (prize money)$2.7M
#8
Series A · Tel Aviv, Tel Aviv · founded 2018 · 15 employees$8Mraised▾
Provider of clinical intelligence services for healthcare organisations
- Aug 2023Series A$5.9M
#9
Seed · Tel Aviv, Tel Aviv · founded 2018 · 21 employees$12Mraised▾
Proprietary platform offering response prediction for dozens of cancer types
- Dec 2022Seed$5M
- Apr 2022Seed$7M
#10
Funding Raised · Nazareth, Northern District · founded 2016 · 6 employees$52.8Mraised▾
Manufacturer of custom implants solutions and surgeon specific instruments
- Jan 2020Grant (prize money)$52.8M
#11
Public · Petah Tikva, Central District · founded 1994 · 8 employees$25.5Mraised▾
Developer of small molecules for autoimmune-inflammatory and cancer diseases
#12
Public · Ness Ziona, Center District · founded 2009 · 31 employees$18.2Mraised▾
Kadimastem is a regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics, primarily for diabetes and neurodegenerative disorders. The company’s proprietary technologies and know-how enable the differentiation of stem cells into insulin-secreting as a range of neural cells (Oligodendrocytes, Astrocytes). Based on its differentiation technologies, the company is advancing two therapeutic programs focused on diabetes mellitus and ALS, where stem cells are differentiated into beta cells (for the diabetes program) and astrocytes (for the ALS program) with the goal of implanting them into patients, and affecting diseases progression. Also collaborating for optimizing drug development through pluripotent stem cell-derived cells.
- Oct 2021Post IPO$5M
- Oct 2018Post IPO$5.2M
- Mar 2018Grant (prize money)$319.4K
- Dec 2016Post IPO$7M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Healthcare coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.